LABIANA HEALTH S.A.EO-10
Research LABIANA HEALTH S.A.EO-10 (8RK) on Bullrun: market cap EUR 52.21M, P/E 17.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8RK
- ExchangeF
- CountrySpain
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 52.21M
- P/E17.1
- Financial periodFY2025
- RevenueEUR 75.18M
- Revenue growth13.5%
- Net incomeEUR 2.57M
- Free cash flow-EUR 2.74M
- Gross margin61.1%
Valuation Snapshot
latest market cap is EUR 52.21M; P/E is 17.1.
Peer valuation comparison
Latest P/E is 17.08x versus a Healthcare sector median of 24.46x (30.2% below).
Latest P/E is 17.08x versus a Spain median of 15.76x (8.4% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 75.18M | EUR 2.57M | -EUR 2.74M | 61.1% | 0.36 | EUR 5.91M | EUR 36.67M | EUR 5.08M |
| FY2024 | EUR 66.26M | EUR 253.45K | EUR 4.15M | 61.8% | 0.04 | EUR 6.74M | EUR 35.39M | EUR 2.87M |
| FY2023 | EUR 58.46M | -EUR 4.42M | -EUR 4.68M | 58.7% | -0.61 | EUR 2.96M | EUR 41.72M | EUR 3.58M |
| FY2022 | EUR 57.85M | -EUR 8.94M | -EUR 774.37K | 56.4% | -1.24 | EUR 2.52M | EUR 38.20M | EUR 7.03M |
| FY2021 | EUR 56.96M | -EUR 1.78M | -EUR 858.72K | 61.4% | -0.25 | EUR 3.28M | EUR 44.76M | EUR 11.59M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 52.21M | 17.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About LABIANA HEALTH S.A.EO-10
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is LABIANA HEALTH S.A.EO-10's market cap?
LABIANA HEALTH S.A.EO-10's market capitalization is EUR 52.21M.
What is LABIANA HEALTH S.A.EO-10's P/E ratio?
LABIANA HEALTH S.A.EO-10's price-to-earnings (P/E) ratio is 17.1.
What does LABIANA HEALTH S.A.EO-10 do?
Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, North America, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized dosage forms, and bacterial vaccines; and Fosfomycin trometamol under the Fosfomicina Labiana brand name. In addition, the company offers contract developments, quality system and manufacturing services.